<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Adlhoch, Cornelia</style></author><author><style face="normal" font="default" size="100%">Concepción Delgado-Sanz</style></author><author><style face="normal" font="default" size="100%">AnnaSara Carnahan</style></author><author><style face="normal" font="default" size="100%">Larrauri, Amparo</style></author><author><style face="normal" font="default" size="100%">Odette Popovici</style></author><author><style face="normal" font="default" size="100%">Nathalie Bossuyt</style></author><author><style face="normal" font="default" size="100%">Isabelle Thomas</style></author><author><style face="normal" font="default" size="100%">Jan Kynčl</style></author><author><style face="normal" font="default" size="100%">Pavel Slezak</style></author><author><style face="normal" font="default" size="100%">Mia Brytting</style></author><author><style face="normal" font="default" size="100%">Raquel Guiomar</style></author><author><style face="normal" font="default" size="100%">Monika Redlberger-Fritz</style></author><author><style face="normal" font="default" size="100%">Jackie Maistre Melillo</style></author><author><style face="normal" font="default" size="100%">Tanya Melillo</style></author><author><style face="normal" font="default" size="100%">Arianne B van Gageldonk-Lafeber</style></author><author><style face="normal" font="default" size="100%">Sierk D Marbus</style></author><author><style face="normal" font="default" size="100%">O'Donnell, Joan</style></author><author><style face="normal" font="default" size="100%">Domegan, Lisa</style></author><author><style face="normal" font="default" size="100%">Joana Gomes Dias</style></author><author><style face="normal" font="default" size="100%">Sonja J Olsen</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effect of neuraminidase inhibitor (oseltamivir) treatment on outcome of hospitalised influenza patients, surveillance data from 11 EU countries, 2010 to 2020.</style></title><secondary-title><style face="normal" font="default" size="100%">Euro Surveill</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Aged</style></keyword><keyword><style  face="normal" font="default" size="100%">Antiviral Agents</style></keyword><keyword><style  face="normal" font="default" size="100%">Enzyme Inhibitors</style></keyword><keyword><style  face="normal" font="default" size="100%">Guanidines</style></keyword><keyword><style  face="normal" font="default" size="100%">Hospital Mortality</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Influenza, Human</style></keyword><keyword><style  face="normal" font="default" size="100%">Neuraminidase</style></keyword><keyword><style  face="normal" font="default" size="100%">Oseltamivir</style></keyword><keyword><style  face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style  face="normal" font="default" size="100%">Zanamivir</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2023 Jan</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">28</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;BackgroundTimely treatment with neuraminidase inhibitors (NAI) can reduce severe outcomes in influenza patients.AimWe assessed the impact of antiviral treatment on in-hospital deaths of laboratory-confirmed influenza patients in 11 European Union countries from 2010/11 to 2019/20.MethodsCase-based surveillance data from hospitalised patients with known age, sex, outcome, ward, vaccination status, timing of antiviral treatment, and hospitalisation were obtained. A mixed effect logistic regression model using country as random intercept was applied to estimate the adjusted odds ratio (aOR) for in-hospital death in patients treated with NAIs vs not treated.ResultsOf 19,937 patients, 31% received NAIs within 48 hours of hospital admission. Older age (60-79 years aOR 3.0, 95% CI: 2.4-3.8; 80 years 8.3 (6.6-10.5)) and intensive care unit admission (3.8, 95% CI: 3.4-4.2) increased risk of dying, while early hospital admission after symptom onset decreased risk (aOR 0.91, 95% CI: 0.90-0.93). NAI treatment initiation within 48 hours and up to 7 days reduced risk of dying (0-48 hours aOR 0.51, 95% CI: 0.45-0.59; 3-4 days 0.59 (0.51-0.67); 5-7 days 0.64 (0.56-0.74)), in particular in patients 40 years and older (e.g. treatment within 48 hours: 40-59 years aOR 0.43, 95% CI: 0.28-0.66; 60-79 years 0.50 (0.39-0.63); ≥80 years 0.51 (0.42-0.63)).ConclusionNAI treatment given within 48 hours and possibly up to 7 days after symptom onset reduced risk of in-hospital death. NAI treatment should be considered in older patients to prevent severe outcomes.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">4</style></issue></record></records></xml>